KRAS and cholangiocarcinoma: For instance, targeted therapies that inhibit specific molecular pathways altered in CCA—such as FGFR2, KRAS, PTEN, CDKN2B, ERBB3, MET, NRAS, CDK6, BRCA1, BRCA2, NF1, PIK3CA, PTCH1, and TSC1—have shown promise in clinical trials, offering hope for more effective management of this challenging disease [4,5].